Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon and Asuragen Sign Agreement for Real-Time PCR Services

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
The Service Center Agreement allows Asuragen to provide real-time PCR services based on Exiqon’s miRCURY LNA™ Universal RT microRNA PCR products.

The Asuragen Genomic Services Division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics (isolation/preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services).

LNA™-based microRNA real-time PCR profiling holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes. Exiqon’s microRNA real-time PCR system combines a Universal RT reaction with LNA™-enhanced PCR primers, which results in unmatched sensitivity and specificity for all sample types.

”Exiqon’s high quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners”, said Carol Berry, Sr. Vice President & GM of Asuragen Genomic Services Division.

In a comment, Sr. VP Sales & Marketing, Henrik Pfundheller of Exiqon said: “We are honored and excited to support Asuragen on the discovery of novel microRNA biomarkers” and added: “Asuragen are experts in their own right in the field of microRNA and this is a great opportunity for us to expand our presence in the U.S. market.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Secures Funding to Accelerate Growth
Exiqon A/S has announced the issue of a senior secured note in the amount of DKK 40 million (‘Note’).
Thursday, November 12, 2015
Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
These new products offer a powerful alternative to existing siRNAs already on the market place.
Tuesday, May 26, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Awarded Global microRNA Research Tools Company of the Year
Company has been recognized as the recipient of the award in light of the excellence that Exiqon has exhibited in the microRNA research space.
Monday, July 08, 2013
Exiqon Announces 2011 Grant Program for MicroRNA Research
Company announces the launch of 2011 global research grant program, open to researchers from academic and non-profit institutions.
Wednesday, February 02, 2011
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators.
Tuesday, December 01, 2009
Exiqon Expands in US; Sales Headquarters Established
Establishing a US presence will liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia.
Thursday, September 14, 2006
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!